Suppressors of Cytokine Signaling 3 Expression in Eosinophils: Regulation by PGE₂ and Th2 Cytokines

Table 1

Clinical characteristics of study subjects.

	Healthy controls	Nonasthmatic eosinophilic bronchitis (NAEB)	Asthma
𝑁	9	8	6
Age (years)	23 (20–30)	40 (31–55)	37(21–61)
Male (%)	4 (44.4%)	4 (50%)	3 (50%)
Atopy (%)	0	5 (62.5%)	3 (50%)
FEV1 predicted^a	105 (100–129)	108.95 (96–115)^§	99,47 (73–110)*
FEV1/FVC^a	85 (79–92)	80.6 (74.5–89.6)	78,91 (77.6–95.2)
Total IgE (kU/L)^a	21.15 (4.52–144)	163 (34.50–605)*	65.2 (57.6–360)*
Eosinophil count (%)	0.14 (0–3.32)	4.40 (1.5–8.39)^†	2.66 (1.34–7.92)*
Sputum eosinophils (%)^a	2.1 (0.1–9.7)	15.9 (2–35)	15.1 (0.6–52.3)
PGE2 in sputum supernatant (pg/mL)^a	2.89 (0.78–5.28)	15.582 (3.81–1336)*	33.8 (12.9–54.7)

FVC: forced vital capacity, FEV1: forced expiratory volume in the first second.
^aMedian (range).
^∗𝑃<.05 (versus healthy control; Kruskal Wallis test; posttest Dunn’s multiple comparison test).
^†𝑃<.01(versus healthy control; Kruskal Wallis test; post test Dunn’s multiple comparison test).
^§𝑃<.05 (versus asthma patients; Kruskal Wallis test; post test Dunn’s multiple comparison test).